Raymond James & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $112K | Sell |
15,225
-475
| -3% | -$3.48K | ﹤0.01% | 3732 |
|
|
2024
Q2 | $89.6K | Sell |
15,700
-2,001
| -11% | -$11.4K | ﹤0.01% | 3703 |
|
|
2024
Q1 | $88.7K | Sell |
17,701
-400
| -2% | -$2K | ﹤0.01% | 3713 |
|
|
2023
Q4 | $163K | Buy |
18,101
+1,150
| +7% | +$10.3K | ﹤0.01% | 3530 |
|
|
2023
Q3 | $132K | Buy |
16,951
+4,651
| +38% | +$36.1K | ﹤0.01% | 3523 |
|
|
2023
Q2 | $119K | Buy |
12,300
+500
| +4% | +$4.84K | ﹤0.01% | 3549 |
|
|
2023
Q1 | $129K | Buy |
+11,800
| New | +$129K | ﹤0.01% | 3558 |
|
|
2022
Q2 | – | Sell |
-11,300
| Closed | -$140K | – | 3859 |
|
|
2022
Q1 | $140K | Buy |
+11,300
| New | +$140K | ﹤0.01% | 3713 |
|
|
2021
Q4 | – | Sell |
-12,600
| Closed | -$279K | – | 3972 |
|
|
2021
Q3 | $279K | Sell |
12,600
-15,390
| -55% | -$341K | ﹤0.01% | 3446 |
|
|
2021
Q2 | $363K | Buy |
+27,990
| New | +$363K | ﹤0.01% | 3283 |
|
|
2021
Q1 | – | Sell |
-10,750
| Closed | -$149K | – | 3832 |
|
|
2020
Q4 | $149K | Buy |
+10,750
| New | +$149K | ﹤0.01% | 3443 |
|
|
2020
Q2 | – | Sell |
-41,495
| Closed | -$602K | – | 3404 |
|
|
2020
Q1 | $602K | Buy |
41,495
+13,050
| +46% | +$189K | ﹤0.01% | 2290 |
|
|
2019
Q4 | $576K | Buy |
+28,445
| New | +$576K | ﹤0.01% | 2614 |
|
|
2017
Q3 | – | Sell |
-29,000
| Closed | -$178K | – | 3264 |
|
|
2017
Q2 | $178K | Buy |
+29,000
| New | +$178K | ﹤0.01% | 2987 |
|